
LABT
Healthcare · Biotechnology · $669,199 market cap
$0.2824-0.08 (-21.4%)Nov 13, 4:28 PM EST
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Sep 30, 2026
EPS trend, 90 days to now · -137.5% over 90 days · 30-day revisions 0 up, 1 down
Beat estimates in 0 of the last 2 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 12, 2026 | Time not confirmed | -0.52 | — | — |
| Aug 28, 2026 | Time not confirmed | 0.65 | -2.75 | -523.1% |
| Jun 3, 2026 | Time not confirmed | — | -1.32 | — |
Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States. The company offers products from its Bisphosphocin class, a novel class of antimicrobial agents a broad range of infections, including those affecting the skin, bladder, and lungs. It also develops Nu-3, a topical antimicrobial for infected diabetic foot ulcers, which…